IVAX Diagnostics Exhibits at AACC

MIAMI--(BUSINESS WIRE)-- IVAX Diagnostics, Inc. (NYSE Amex:IVD), a fully integrated in vitro diagnostics company, announced that its three wholly-owned subsidiaries – Diamedix Corporation, ImmunoVision, Inc. and Delta Biologicals, S.r.l. – are participating as exhibitors in the 2011 American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, which is currently ongoing in Atlanta, Georgia.

Kevin Clark, President, Chief Executive Officer and Chief Operating Officer of IVAX Diagnostics, said, “We are pleased to be participating as an exhibitor at the AACC, which is the largest clinical exposition in the world. We are showcasing our suite of products, including our Mago® 4S automated ELISA and IFA instrumentation system that received 510(k) clearance from the U.S. Food and Drug Administration earlier this year, at booth #3805 at the event. ERBA Diagnostics Mannheim GmbH, an in vitro diagnostics company headquartered in Germany which owns, directly or indirectly, approximately 77.8% of the issued and outstanding shares of our common stock, is also participating as an exhibitor at the AACC event and is showcasing its suite of products in booth #3705.”

About IVAX Diagnostics, Inc.

IVAX Diagnostics, Inc. (www.ivaxdiagnostics.com), headquartered in Miami, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its three subsidiaries: Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), and ImmunoVision, Inc. (U.S.).

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of IVAX Diagnostics, Inc. Investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in IVAX Diagnostics’ filings with the Securities and Exchange Commission, including, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in such filings.



CONTACT:

IVAX Diagnostics, Inc.
Kevin Clark, CEO, COO and President, 305-324-2300

KEYWORDS:   United States  North America  Florida  Georgia

INDUSTRY KEYWORDS:   Health  AIDS  Biotechnology  Hospitals  Infectious Diseases  Medical Devices  Pharmaceutical  Medical Supplies  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.